SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 126273.
  • 2
    Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 413.
  • 3
    Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 228190.
  • 4
    Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62: 153341.
  • 5
    Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis Rheum 1997; 40: 197683.
  • 6
    Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003; 30: 60317.
  • 7
    Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159: 88794.
  • 8
    Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42: 14529.
  • 9
    Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 2009; 48: 1349.
  • 10
    Muscle Study Group. Randomized pilot trial of BINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001; 57: 156670.
  • 11
    Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 46572.
  • 12
    Sanner H, Kirkhus E, Merckoll E, Tollisen A, Roisland M, Lie BA, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case–control study. Arthritis Care Res (Hoboken) 2010; 62: 110311.
  • 13
    Jain M, Smith M, Cintas H, Koziol D, Wesley R, Harris-Love M, et al. Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006; 26: 517.
  • 14
    Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 4954.
  • 15
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 16
    Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995; 38: 121824.
  • 17
    Mercer LK, Moore TL, Chinoy H, Murray AK, Vail A, Cooper RG, et al. Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 2010; 49: 1699705.
  • 18
    Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 134653.
  • 19
    Neri R, Mosca M, Stampacchia G, Vesprini E, Tavoni A, d'Ascanio A, et al. Functional and isokinetic assessment of muscle strength in patients with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 2559.
  • 20
    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 21
    Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. J Rheumatol 2001; 28: 110611.
  • 22
    Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM. Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995; 22: 32631.
  • 23
    Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 2005; 44: 838.
  • 24
    Alexanderson H, Lundberg IE, Stenstrom CH. Development of the Myositis Activities Profile: validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 2002; 29: 238692.
  • 25
    Takken T, Elst E, Spermon N, Helders PJ, Prakken AB, van der Net J. The physiological and physical determinants of functional ability measures in children with juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42: 5915.
  • 26
    Maillard SM, Jones R, Owens C, Pilkington C, Woo P, Wedderburn LR, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004; 43: 6038.
  • 27
    Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the Myositis Damage Index. Arthritis Rheum 2009; 60: 342535.
  • 28
    Apaz MT, Saad-Magalhaes C, Pistorio A, Ravelli A, de Oliveira Sato J, Marcantoni MB, et al, for the Paediatric Rheumatology International Trials Organisation. Health-related quality of life of patients with juvenile dermatomyositis: results from the Paediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009; 61: 50917.
  • 29
    Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001; 19 Suppl: S19.
  • 30
    Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595603.
  • 31
    Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 22139.
  • 32
    Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum 2004; 51: 36570.
  • 33
    Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) 2010; 62: 21925.
  • 34
    Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62: 6372.
  • 35
    Whiting-O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999; 42: 236571.
  • 36
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 44758.
  • 37
    Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the Myositis Disease Activity Assessment Tool. Arthritis Rheum 2008; 58: 35939.
  • 38
    Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti–Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56: 312531.
  • 39
    Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 92737.
  • 40
    Cresswell L, Yee CS, Farewell V, Rahman A, Teh LS, Griffiths B, et al. Numerical scoring for the classic BILAG index. Rheumatology (Oxford) 2009; 48: 154852.
  • 41
    Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease Activity Score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 715.
  • 42
    Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31: 16449.
  • 43
    Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil, a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) 2010; 62: 144651.
  • 44
    Schmeling H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford) 2011; 50: 88593.
  • 45
    Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002; 41: 226.
  • 46
    Sadjadi R, Rose MR. What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry 2010; 81: 11646.
  • 47
    Regardt M, Welin HE, Alexanderson H, Lundberg IE. Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford) 2011; 50: 57885.
  • 48
    Alexanderson H, Stenstrom CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology (Oxford) 1999; 38: 60811.
  • 49
    Alexanderson H, Stenstrom CH, Jenner G, Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000; 29: 295301.
  • 50
    Landgraf JM, Abetz L, Ware JE. The CHQ user's manual. 1st ed. Boston: The Health Institute, New England Medical Center; 1996.
  • 51
    Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004; 16: 56670.
  • 52
    Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin Exp Rheumatol 2001; 19 Suppl: S1172.
  • 53
    Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H. The Juvenile Arthritis Quality of Life Questionnaire: development of a new responsive index for juvenile rheumatoid arthritis and juvenile spondyloarthritides. J Rheumatol 1997; 24: 73846.
  • 54
    Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum 2002; 46: 71425.
  • 55
    Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 24854.
  • 56
    Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 936.
  • 57
    Sultan SM, Allen E, Cooper RG, Agarwal S, Kiely P, Oddis CV, et al. Interrater reliability and aspects of validity of the Myositis Damage Index. Ann Rheum Dis 2011; 70: 12726.
  • 58
    Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009; 48: 15417.
  • 59
    Mathiesen PR, Zak M, Herlin T, Nielsen SM. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 2010; 28: 7829.
  • 60
    Muscle Study Group. Randomized pilot trial of high-dose β INF1a in patients with inclusion body myositis. Neurology 2004; 63: 71820.
  • 61
    Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006; 66 Suppl: S1234.
  • 62
    Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58: 10817.
  • 63
    Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 7126.
  • 64
    Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 3237.
  • 65
    Brussock CM, Haley SM, Munsat TL, Bernhardt DB. Measurement of isometric force in children with and without Duchenne's muscular dystrophy. Phys Ther 1992; 72: 10514.
  • 66
    Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001; 57: 54850.
  • 67
    Stoll T, Bruhlmann P, Stucki G, Seifert B, Michel BA. Muscle strength assessment in polymyositis and dermatomyositis evaluation of the reliability and clinical use of a new, quantitative, easily applicable method. J Rheumatol 1995; 22: 4737.
  • 68
    Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. Neurology 1994; 44: 4426.
  • 69
    The FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997; 48: 3846.
  • 70
    Meldrum D, Cahalane E, Conroy R, Fitzgerald D, Hardiman O. Maximum voluntary isometric contraction: reference values and clinical application. Amyotroph Lateral Scler 2007; 8: 4755.
  • 71
    Stoll T, Huber E, Seifert B, Michel BA, Stucki G. Maximal isometric muscle strength: normative values and gender-specific relation to age. Clin Rheumatol 2000; 19: 10513.
  • 72
    Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, et al. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve 2001; 24: 78793.
  • 73
    Personius KE, Pandya S, King WM, Tawil R, McDermott MP. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 1994; 74: 25363.
  • 74
    Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008; 37: 4736.
  • 75
    Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132: 153644.
  • 76
    Alexanderson H, Broman L, Tollback A, Josefson A, Lundberg IE, Stenstrom CH. Functional Index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006; 55: 11422.
  • 77
    Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol 1996; 23: 13804.
  • 78
    Alexanderson H, Dastmalchi M, Esbjornsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum 2007; 57: 76877.
  • 79
    Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 37781.
  • 80
    Nordenskiold UM, Grimby G. Grip force in patients with rheumatoid arthritis and fibromyalgia and in healthy subjects: a study with the Grippit instrument. Scand J Rheumatol 1993; 22: 149.
  • 81
    Alexanderson H, Bergegard J, Alemo-Munters L, Dastmalchi M, Lundberg IE. Patients with idiopathic inflammatory myopathies have low muscle endurance rather than low muscle strength [abstract]. Arthritis Rheum 2009; 60 Suppl: S307.
  • 82
    World Health Organization. International classification of impairment, disability and handicap: β-2 draft, full version. Geneva: World Health Organization; 1999.
  • 83
    Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80: 118693.
  • 84
    The ALS CNFT Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53: 1417.
  • 85
    Yassaee M, Fiorentino D, Okawa J, Taylor L, Coley C, Troxel AB, et al. Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2010; 162: 66973.
  • 86
    Chock M, Goreshi R, Werth VP, Fiorentino D. Quantitative assessment of disease severity in dermatomyositis [abstract]. J Invest Dermatol 2010; 130 Suppl: S50.
  • 87
    Goreshi R, Okawa J, Rose M, Feng R, Lee LA, Hansen C. Evaluation of reliability, validity, and responsiveness of the CDASI and CAT-BM [abstract]. Arthritis Rheum 2010; 62 Suppl: S381.
  • 88
    Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007; 46: 160611.
  • 89
    Huber AM, Lachenbruch PA, Dugan EM, Miller FW, Rider LG, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum 2008; 59: 3526.
  • 90
    Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum 2008; 59: 21421.
  • 91
    Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 23844.
  • 92
    Carroll CL, Lang W, Snively B, Feldman SR, Callen J, Jorizzo JL. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008; 158: 34550.
  • 93
    Charman CR, Venn AJ, Williams HC. Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 1999; 140: 10911.
  • 94
    Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 70713.
  • 95
    Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 143340.
  • 96
    Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 1997; 108: 1037.
  • 97
    Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 272639.
  • 98
    Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 10510.
  • 99
    Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006; 126: 124450.
  • 100
    Nijsten T, Sampogna F, Abeni D. Categorization of Skindex-29 scores using mixture analysis. Dermatology 2009; 218: 1514.
  • 101
    Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54: 21720.
  • 102
    Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 2106.
  • 103
    Loo WJ, Diba V, Chawla M, Finlay AY. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003; 148: 27984.
  • 104
    Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 9971035.
  • 105
    Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 16980.
  • 106
    De Korte J, Mombers FM, Sprangers MA, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138: 12217.
  • 107
    Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 9429.
  • 108
    Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003; 148: 28590.
  • 109
    Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol 1999; 141: 698702.
  • 110
    Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales: a measure of the impact of skin diseases. Br J Dermatol 1997; 136: 2026.
  • 111
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
  • 112
    Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 65964.